| abstract |
Substituted pyridine of formula (IA) is prepared by reacting a suitably substituted pyridylaldehyde with Grignard or Wittig reagent and reducing the product obtained suitably. Pyridine of formula (IA) is suitable as active compound in pharmaceutical formulations, especially pharmaceutical formulations for inhibiting cholesterol ester transfer proteins. 3-Heteroalkyl-aryl substituted pyridine of formula (IB) is prepared from correspondingly protected and correspondingly substituted pyridine in a hydroxy group. The compounds of formula (IB) according to the invention are suitable as compounds which are active in pharmaceutical preparations, in particular pharmaceutical preparations for the treatment of hyperlipoproteinemia. Substituted pyridines and benzenes of formula IC are prepared by the procedures disclosed herein and are useful as active ingredients in pharmaceutical formulations, particularly pharmaceutical formulations for the treatment of glucagon-mediated diseases such as diabetes, by inhibiting glucagon receptors. |